Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬ £¬£¬ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

¾©ÐÂÒ©Òµ1ÀàÅÁ½ðÉ­ÐÂÒ©»ñÅúÁÙ´²

2024-04-07
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20240407160022.jpg

Ò½ÏßÒ©ÎÅ

1. 4ÔÂ7ÈÕ£¬£¬ £¬£¬ £¬¾ÝCDE¹ÙÍøÏÔʾ£¬£¬ £¬£¬ £¬Õã½­¾©ÐÂÒ©Òµ¹É·ÝÓÐÏÞ¹«Ë¾1À໯ҩÐÂÒ©JX2105½ºÄÒ»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬ £¬£¬ £¬Ë³Ó¦Ö¢ÎªÅÁ½ðÉ­²¡¡£¡£¡£

2. 4ÔÂ6ÈÕ£¬£¬ £¬£¬ £¬°¢Ë¹Àû¿µºÍµÚÒ»Èý¹²ÅäºÏÐû²¼Enhertu£¨µÂÇúÍ×Öéµ¥¿¹£©ÒÑ»ñÃÀ¹úFDA¼ÓËÙÅú×¼£¬£¬ £¬£¬ £¬ÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýÈ«ÉíÖÎÁÆÇÒûÓÐÁîÈËÖª×ãµÄÌæ»»ÖÎÁƼƻ®µÄ²»¿ÉÇгý»ò×ªÒÆÐÔHER2ÑôÐÔ£¨IHC 3+£©ÊµÌåÁö³ÉÈË»¼Õß¡£¡£¡£

3. ¿ËÈÕ£¬£¬ £¬£¬ £¬ÁìŵҽҩÐû²¼£¬£¬ £¬£¬ £¬ÆäÐÂÒ»´ú²¹Ìå°ÐÏòÒ©ÎïSLN12140µÄ1ÆÚÁÙ´²Ñо¿ÉêÇë»ñµÃ°Ä´óÀûÑÇÈËÀàÑо¿Â×ÀíίԱ»á£¨HREC£©µÄÅú×¼¡£¡£¡£²¹Ìå×÷ΪÈËÌåѪÇåÖеÄÒ»ÖÖÂѰ×ÖÊÖֱ𣬣¬ £¬£¬ £¬ÔÚÈËÌ忹ѬȾÃâÒß¡¢×éÖ¯ÐÞ¸´ºÍÔÙÉú·½ÃæÊ©Õ¹×ÅÒªº¦µÄÐÄÀíѧ¹¦Ð§¡£¡£¡£

4. 4ÔÂ4ÈÕ£¬£¬ £¬£¬ £¬Ô·¶«ÉúÎïÐû²¼Í¨¸æ£¬£¬ £¬£¬ £¬¾ÆÊ¯Ëá²¼ÍзÈŵעÉäÒºÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¡¶Ò©Æ·×¢²áÖ¤Êé¡·¡£¡£¡£¾ÆÊ¯Ëá²¼ÍзÈŵעÉäÒºÖ÷ÒªÒòËØÎª¾ÆÊ¯Ëá²¼ÍзÈŵ£¬£¬ £¬£¬ £¬Ë³Ó¦Ö¢ÎªÓÃÓÚÖÎÁÆÖÖÖÖ°©ÐÔÌÛÍ´¡¢ÊÖÊõºóÌÛÍ´¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. 4ÔÂ7ÈÕ£¬£¬ £¬£¬ £¬»ùÒò±à¼­Æ½Ì¨Ðͼ¼ÊõÆóÒµÒýÕý»ùÒò¿Æ¼¼ÓÐÏÞ¹«Ë¾Ðû²¼Íê³ÉÍòÍòÃÀÔªµÄPre-A+ÂÖÈÚ×Ê¡£¡£¡£ÕÙļ×ʽð½«ÓÃÓÚÖ§³Ö¹«Ë¾ÐÂÒ»´ú»ùÒò±à¼­¹¤¾ßµÄ¿ª·¢Óë²úÆ·¹ÜÏߵĿìËÙÍÆ½ø£¬£¬ £¬£¬ £¬¼ÌÐøÌáÉý²úÆ·µÄÑз¢ºÍ¹¤Òµ»¯ÄÜÁ¦£¬£¬ £¬£¬ £¬Ñз¢ºÍ½¨ÉèÌåÄÚ»ùÒò±à¼­Ò©ÎïÖÆ¼ÁµÄ¹æÄ£Éú²ú¼¼ÊõºÍϵͳ£¬£¬ £¬£¬ £¬Ê¹²úÆ·ÏßÄܹ»¿ìËÙ´ÓÔçÆÚÑо¿½×¶Î½øÈëÒ©ÎïÉ걨µÄÁÙ´²Ç°Ñо¿ºÍÁÙ´²½×¶Î£¬£¬ £¬£¬ £¬²¢½øÒ»²½ÍêÉÆÑз¢ºÍ¹ÜÀíÍŶÓ¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. ¿ËÈÕ£¬£¬ £¬£¬ £¬ÈÕÄÚÍß´óѧ£¨UNIGE£©µÄÒ»Ö§Ñо¿ÍŶÓÓëÉúÎï¼¼Êõ¹«Ë¾FoRx TherapeuticsÏàÖú£¬£¬ £¬£¬ £¬¡°²ð½â¡±ÁËPARPÒÖÖÆ¼ÁÆð×÷Óõķ½·¨£¬£¬ £¬£¬ £¬·¢Ã÷¿ÉÒÔͨ¹ý²¿·Ö×è¶ÏPARPÂѰ׵ÄÌØÒìÐÔ»îÐÔ£¬£¬ £¬£¬ £¬Î¬³Ö¶Ô°©Ï¸°ûµÄɪË×÷Ó㬣¬ £¬£¬ £¬Í¬Ê±ÓÖïÔÌ­¶Ô¿µ½¡Ï¸°ûµÄ¶¾ÐÔ¡£¡£¡£Ïà¹Ø·¢Ã÷¶ÔË¢ÐÂÕâÀà°ÐÏòÁÆ·¨¾ßÓÐÖ÷ÒªµÄÖ¸µ¼ÒâÒå¡£¡£¡£

[1]Petropoulos, M., Karamichali, A., Rossetti, G.G. et al. Transcription¨Creplication conflicts underlie sensitivity to PARP inhibitors. Nature (2024). https://doi.org/10.1038/s41586-024-07217-2

Ïà¹ØÐÂÎÅ
Õã½­Ê×¼Ò·ÂÖÆÒ©Ò»ÖÂÐÔÆÀ¼ÛÏÖ³¡¼ì²éÊÂÇéÍê³É---¾©ÐÂÒ©Òµ/ÈðÊæ·¥ËûÍ¡¸Æ
2017-06-29
¿ªÕ¹·ÂÖÆÒ©ÖÊÁ¿ºÍÁÆÐ§Ò»ÖÂÐÔÆÀ¼Û£¬£¬ £¬£¬ £¬Êǹú¼ÒʳÎïÒ©Æ·î¿Ïµ×ܾÖÉҩƷÉóÅúÖÆ¶ÈˢеÄÖ÷ÒªÄÚÈÝ£¬£¬ £¬£¬ £¬Ò²ÊÇÍÆ½øÒ½Ò©¹¤Òµ¹©Ó¦²à½á¹¹ÐÔˢеÄÖØ·Å×Ý´ë¡£¡£¡£
¾©ÐÂÒ©Òµ¿¹ñ²ðコÄÒÁÙ´²ÉêÇë»ñÊÜÀíØ­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2022-07-04
7ÔÂ2ÈÕ£¬£¬ £¬£¬ £¬¾©ÐÂÒ©ÒµµÝ½»µÄJBPOS0101½ºÄÒÁÙ´²ÊÔÑéÉêÇëÒÑ»ñµÃÊÜÀí¡£¡£¡£¹ûÈ»×ÊÁÏÏÔʾ£¬£¬ £¬£¬ £¬JBPOS0101ÊǺ«¹úBio-Pharm Solutions¹«Ë¾¿ª·¢µÄÒ»¿î¿¹ñ²ðïÐÂÒ©£¬£¬ £¬£¬ £¬¾©ÐÂÒ©ÒµÓÚ2021Äê8ÔÂͨ¹ýÏàÖú»ñµÃÁ˸ÃÒ©ÔÚÖйúµØÇøµÄ¶À¼ÒÈ¨Òæ£¬£¬ £¬£¬ £¬´ËÏîÏàÖúÊ׸¶¿îºÍÀï³Ì±®¸¶¿î¸ß´ï4000ÍòÃÀÔª¡£¡£¡£
½³ÐÄÑÐÒ©£¬£¬ £¬£¬ £¬´ðºÃ¿Í»§Öª×ã¾í | ¾©ÐÂÒ©ÒµÊÚÓèÃÀ¸ß÷DMPKÍŶӡ¢ÐÂÒ©×¢²á²¿¡°Í»³öТ˳ÍŶӽ±¡±ÊâÈÙ
2023-05-31
ÃÀ¸ß÷½«¼ÌÐø¼á³Ö¶Ô¿ÆÑеijõÐĺÍÈȰ®£¬£¬ £¬£¬ £¬³Ð¼ÌïÆ¶ø²»ÉáµÄ¾«Éñ£¬£¬ £¬£¬ £¬¹¥¼á¿ËÄÑ¡¢×ÖÕå¾ä×㬣¬ £¬£¬ £¬Æð¾¢Ó¦¶ÔÐÐÒµÌôÕ½£¬£¬ £¬£¬ £¬ÒԸ߱ê×¼µÄЧÀͼùÐжԿͻ§µÄÔÊÐí£¬£¬ £¬£¬ £¬Ô²ÂúÍê³Éÿһ¸öÏîÄ¿µÄ×îÖÕ½»¸¶£¡
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿